NEWTOWN, Pa., Sept. 29, 2022 (GLOBE NEWSWIRE) — Helius Medical Technologies, Inc. HSDT (“Helius” or the “Company”), a neuro-wellbeing neurotechnology company, announced today that Dane Andreeff, President and Chief Executive Officer, and Jeff Mathiesen, Chief Financial Officer, at ROTH Capital Partners Inaugural Healthcare Opportunities Conference will present as follows:
| Date: | Thursday October 6, 2022 |
| Time: | 8:45 a.m. ET |
| Location: | The Yale Club, New York, NY |
Investors and participants wishing to arrange a face-to-face meeting with Helius management are encouraged to contact their Roth Capital representative to arrange a meeting.
About Helius Medical Technologies, Inc.
Helius Medical Technologies is a leading medical device neurotech company focused on neurological deficits using non-implantable platform technologies that enhance the brain’s ability to compensate and promote neuroplasticity, thereby improving the lives of people living with neurological disorders becomes.
The company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS®). For more information visit www.heliusmedical.com.
About the PoNS device and PoNS therapy
The Wearable Neuromodulation Stimulator (PoNS) is an innovative non-surgical medical device, including a controller and mouthpiece, that delivers electrical stimulation to the surface of the tongue to improve balance and gait. The PoNS device is indicated in the United States for the short-term treatment of gait disturbances due to mild to moderate symptoms of multiple sclerosis (“MS”) and is intended to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age or older only as directed by a physician. Helius is advancing PoNS post-registration research in MS through a recently launched Therapeutic Experience Program (TEP) designed to partner with neurologists and neurorehabilitation therapists at 10-12 US centers of excellence who express an interest in becoming early adopters to become of PoNS. ..
